Elicio Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company that develops lymph node-targeted immunotherapies based on its proprietary Amphiphile (AMP) platform to treat cancers, including mutant KRAS-driven solid tumors such as pancreatic ductal adenocarcinoma and colorectal cancer. The company offers ELI-002, a multivalent AMP peptide vaccine in Phase 2 trials (AMPLIFY-7P) targeting seven common KRAS mutations; ELI-007, a preclinical AMP vaccine for BRAF-driven cancers; ELI-008, a preclinical AMP vaccine for p53-mutated cancers; and earlier-stage candidates including ELI-004 (adjuvant), ELI-011 (hematological cancers), and ELI-012 (mKRAS TCR T cell amplifier). Founded in 2011 and headquartered in Boston, Massachusetts, Elicio conducts operations primarily in the United States with clinical trials at international sites. Recent developments include a $10 million senior secured financing from GKCC, LLC in June 2025 to fund operations into Q1 2026 and support the AMPLIFY-7P Phase 2 interim analysis; alignment with the FDA on ELI-002 Phase 3 registrational strategy; publication of updated Phase 1 AMPLIFY-201 data in Nature Medicine showing 16.3-month median recurrence-free survival; an investigator-initiated Phase 1 neoadjuvant trial for ELI-002 by Memorial Sloan Kettering Cancer Center funded by the Lustgarten Foundation; and the appointment of Marc J. Wolfgang as Chief Technology Officer in November 2025.
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
Elicio Therapeutics Pancreatic Cancer Study Disappoints
ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.
Elicio shares tumble after pancreatic cancer therapy misses mid-stage study goal
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out
Elicio Therapeutics Reports Inducement Grants